Cargando…

Antiphospholipid syndrome combined with acute coronary syndrome: Case report

RATIONALE: Antiphospholipid syndrome (APS) combined with acute coronary syndrome (ACS) is rarely reported. PATIENT CONCERNS: One male patient with APS was admitted to our hospital, who had recent unstable angina (UA). DIAGNOSIS: The preliminary diagnosis of ACS and UA (BraunwaldiB) was then made. IN...

Descripción completa

Detalles Bibliográficos
Autores principales: Shan, Yuan, Wang, Ping, Liu, JingHua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6320188/
https://www.ncbi.nlm.nih.gov/pubmed/30572471
http://dx.doi.org/10.1097/MD.0000000000013613
Descripción
Sumario:RATIONALE: Antiphospholipid syndrome (APS) combined with acute coronary syndrome (ACS) is rarely reported. PATIENT CONCERNS: One male patient with APS was admitted to our hospital, who had recent unstable angina (UA). DIAGNOSIS: The preliminary diagnosis of ACS and UA (BraunwaldiB) was then made. INTERVENTIONS: This patient received secondary preventative therapy for coronary heart disease (CHD) in combination with percutaneous transluminal coronary angioplasty (PTCA) and implantation of NeoVas Bioresorbable Coronary Scaffold. OUTCOMES: The patient was followed up, without new UA episodes were observed at 6 months, 1 year, and 2 year after surgery, respectively. LESSONS: It was thus concluded that percutaneous coronary intervention (PCI) is effective for APS patients and NeoVas scaffold implantation is presumed safe.